Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial

Bosutinib is an oral, dual SRC/ABL1 tyrosine kinase inhibitor for resistant/intolerant chronic myeloid leukaemia (CML). We assessed the efficacy and safety of bosutinib 500 mg/d (n = 250) versus imatinib 400 mg/d (n = 252) after >24 months from accrual completion in newly diagnosed chronic phase...

Descripción completa

Detalles Bibliográficos
Autores principales: Brümmendorf, Tim H, Cortes, Jorge E, de Souza, Cármino Antonio, Guilhot, Francois, Duvillié, Ladan, Pavlov, Dmitri, Gogat, Karïn, Countouriotis, Athena M, Gambacorti-Passerini, Carlo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2015
Materias:
Haematological Malignancy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4274978/
https://www.ncbi.nlm.nih.gov/pubmed/25196702
http://dx.doi.org/10.1111/bjh.13108

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4274978/
https://www.ncbi.nlm.nih.gov/pubmed/25196702
http://dx.doi.org/10.1111/bjh.13108

Ejemplares similares